Prometheus Biosciences is a biopharmaceutical company that develops and commercializes innovative therapies and diagnostic products for inflammatory bowel diseases. Its lead product, PRA023, is a humanized antibody in Phase IIa trials for ulcerative colitis, Crohn's disease, and systemic sclerosis-associated interstitial lung disease. The company also has various other biologics and small molecule products in its product pipeline for IBD and other immune-mediated diseases and collaborations with pharmaceutical giants such as Takeda and Dr. Falk Pharma.